^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    S95029

    i
    Other names: S 095029, S-95029, S 95029, Sym-025, Sym 025, S95029, Sym025, S095029, S-095029
    Associations

    News

    Trials
    Company:
    Servier
    Drug class:
    NKG2A inhibitor
    Related drugs:
    Associations

    News

    Trials
    28d
    CL1-95029-001: S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers (clinicaltrials.gov)
    P1, N=41, Completed, Institut de Recherches Internationales Servier | Active, not recruiting --> Completed
    Trial completion
    |
    futuximab/modotuximab (S95026) • S95029 • Sym021
    1m
    Phase 1 multicenter study of the NKG2A targeting antibody S095029 as a single agent and in combination with anti-PD-1 in patients with advanced malignancies. (PubMed, J Immunother Cancer)
    The anti-NKG2A antibody S095029 in combination with anti-PD-1 Sym021 demonstrated a favorable safety profile and exhibited signal of antitumor activity in unselected, heavily pretreated patients with advanced malignancies.
    Clinical • P1 data • Journal • PD(L)-1 Biomarker • IO biomarker • First-in-human
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • HLA-E (Major Histocompatibility Complex, Class I, E) • KLRC1 (Killer Cell Lectin Like Receptor C1) • KLRD1 (Killer Cell Lectin Like Receptor D1)
    |
    S95029 • Sym021
    2ms
    Keynote E70: A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers. (clinicaltrials.gov)
    P1/2, N=48, Active, not recruiting, Servier Bio-Innovation LLC | Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Aug 2026 --> Aug 2027
    Trial completion date • Trial primary completion date • MSI-H • dMMR
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • S95029
    3ms
    Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P1/2, N=100, Active, not recruiting, Servier Bio-Innovation LLC | N=74 --> 100
    Enrollment change • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Libtayo (cemiplimab-rwlc) • S95018 • S95029
    4ms
    Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P1/2, N=74, Active, not recruiting, Servier Bio-Innovation LLC | Recruiting --> Active, not recruiting | N=176 --> 74
    Enrollment closed • Enrollment change • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Libtayo (cemiplimab-rwlc) • S95018 • S95029
    7ms
    CL1-95029-001: S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers (clinicaltrials.gov)
    P1, N=51, Active, not recruiting, Institut de Recherches Internationales Servier | Trial completion date: Jun 2025 --> Mar 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF V600E • KRAS wild-type
    |
    futuximab/modotuximab (S95026) • S95029 • Sym021
    8ms
    Keynote E70: A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers. (clinicaltrials.gov)
    P1/2, N=38, Active, not recruiting, Servier Bio-Innovation LLC | Recruiting --> Active, not recruiting | Trial completion date: Jun 2029 --> Aug 2026
    Enrollment closed • Trial completion date • MSI-H • dMMR
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • S95029
    over1year
    CL1-95029-001: S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers (clinicaltrials.gov)
    P1, N=51, Active, not recruiting, Institut de Recherches Internationales Servier | Trial completion date: Jan 2025 --> Jun 2025
    Trial completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF V600E • KRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type
    |
    futuximab/modotuximab (S95026) • S95029 • Sym021
    over1year
    Keynote E70: A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers. (clinicaltrials.gov)
    P1/2, N=32, Recruiting, Servier Bio-Innovation LLC | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • S95029
    almost2years
    S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers (clinicaltrials.gov)
    P1, N=51, Active, not recruiting, Institut de Recherches Internationales Servier | Trial completion date: Jul 2024 --> Jan 2025
    Trial completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    futuximab/modotuximab (S95026) • S95029 • Sym021
    almost2years
    Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P1/2, N=176, Recruiting, Servier Bio-Innovation LLC | Not yet recruiting --> Recruiting
    Enrollment open • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Libtayo (cemiplimab-rwlc) • S95018 • S95029
    2years
    S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers (clinicaltrials.gov)
    P1, N=51, Active, not recruiting, Institut de Recherches Internationales Servier | Trial completion date: Feb 2024 --> Jul 2024
    Trial completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF V600E • KRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type
    |
    futuximab/modotuximab (S95026) • S95029 • Sym021